Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Competitive Landscape, Pipeline and Market Analysis, 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Competitive Landscape, Pipeline and Market Analysis, 2017" report to their offering.

Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Competitive Landscape, Pipeline and Market Analysis, 2017 provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Chimeric Antigen Receptor (CAR) T cell Immunotherapy.

This report provides information on the therapeutic development based on Chimeric Antigen Receptor (CAR) T cell Immunotherapy mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs.

This report also assesses the Chimeric Antigen Receptor (CAR) T cell Immunotherapy therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.

Scope:

- The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy

- The report provides the marketed drugs information including its sales, development activities and details of patent expiry

- The report provides the insight of current and future market for Chimeric Antigen Receptor (CAR) T cell Immunotherapy

- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

- Coverage of the Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

- The report reviews key players involved in the therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy and also provide company profiling

- The report also gives the information of dormant pipeline projects

- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages

- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Companies Mentioned

- Juno Therapeutics

- Miltenyi Biotec

- ZMKS International Cancer Therapies Biotechnologies Co. Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/tvvwn2/chimeric_antigen

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs